PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Panacea Biotec reported audited financial results for Q4 and FY ended March 31, 2026. Consolidated total income grew to ₹63,977 Lakh (vs ₹55,909 Lakh in FY 2025), but the company remained in loss. Consolidated net loss after tax stood at ₹716 Lakh for FY 2026 (narrower than ₹872 Lakh loss in FY 2025), while standalone net loss was ₹2,988 Lakh (vs ₹1,523 Lakh). The Vaccines segment reported a loss of ₹2,684 Lakh while Formulations was profitable at ₹1,947 Lakh. The board has passed over dividend for FY 2025-26 due to losses. Additionally, the board appointed Mr. Rajinder Singh Manku as a non-executive independent director for a 5-year term starting July 1, 2026, subject to shareholder approval. The auditors issued an unmodified opinion. The company highlighted going concern risks as standalone retained earnings are negative at ₹21,782 Lakh, though group retained earnings remain positive at ₹77,605 Lakh.
Revenue growth is positive but persistent losses and dividend skipping signal financial stress. The independent director appointment is a governance positive but does not offset the underlying profitability concerns. Investors should monitor cash flow and debt levels.